CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Maddocks: So let ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Lower socioeconomic status is associated with poor survival in lymphoma. Patients with follicular lymphoma (FL) lived longer if they had private insurance, according to a study that examined patient ...
Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset This multi-year study will enroll FL patients to generate a comprehensive, multi-omic dataset using ...
Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results